Hox Therapeutics appoints Karl Keegan as CEO

Dr Karl Keegan has over 25 years’ experience in the biotech/pharma sector. Following his MPhil/PhD degrees at Cambridge, he did postdoctoral work at Baylor College of Medicine, Texas before moving to industry. From 2009, he has held key executive positions including CFO/corporate development roles at Pharming Group NV, Vectura Group Plc and Shield Therapeutics Plc.

James Culverwell, Chairman of Hox Therapeutics, said: “We are very pleased to welcome Karl at this critical stage in the Company’s development.  As we are preparing to move into phase I proof-of-concept studies with our lead product, we are expanding the executive leadership team with experts in clinical oncology and operations, regulatory affairs and manufacturing as HOX transitions to be a clinical-stage biotech company.”